EMA Authorised: Ryzodeg (insulin aspart;insulin degludec) — Novo Nordisk A/S

View source ↗

Summary

The European Medicines Agency authorised Ryzodeg (insulin aspart and insulin degludec) from Novo Nordisk A/S for diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Ryzodeg (insulin degludec/insulin aspart)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Novo Nordisk A/S. Decision date: 15/02/2024